INmune Bio (INMB) Set to Post Earnings on Thursday

INmune Bio (NASDAQ:INMB) is projected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.1467) per share and revenue of $1.88 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.16.

INmune Bio Trading Up 0.6%

Shares of NASDAQ INMB opened at $1.61 on Thursday. INmune Bio has a 12-month low of $1.09 and a 12-month high of $2.60. The business’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $1.74.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings upgraded shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, INmune Bio currently has an average rating of “Moderate Buy”.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company developing immunotherapies that target the innate immune system. The company’s research focuses on addressing chronic inflammation and improving immune responses in neurological disorders and cancer.

Its lead product candidate, XPro, is an investigational selective inhibitor of soluble tumor necrosis factor (TNF), an inflammatory signaling protein. INmune Bio is evaluating XPro in conditions associated with neuroinflammation, including Alzheimer’s disease and depression-related disorders.